Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 13/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242768 | 0.85 | KCNA5 (0.68) | KCNA5KCNH2SMN1; SMN2 | |
| SCHEMBL1243276 | 0.84 | KCNA5 (0.67) | KCNA5KCNH2SMN1; SMN2 | |
| SCHEMBL1242759 | 0.83 | KCNA5 (0.65) | KCNA5KCNH2SMN1; SMN2 | |
| SCHEMBL1243547 | 0.82 | KCNA5 (0.70) | KCNA5KCNH2CYP3A4 | |
| SCHEMBL1243165 | 0.74 | KCNA5 (0.52) | KCNA5KCNH2CYP3A4SMN1; SMN2 | |
| SCHEMBL1243030 | 0.73 | KCNA5 (0.45) | KCNA5KCNH2CYP3A4CYP3A5UBE2M | |
| SCHEMBL1241966 | 0.70 | KCNA5 (0.71) | KCNA5KCNH2CYP3A4CYP3A5 | |
| SCHEMBL1242561 | 0.67 | KCNA5 (1.00) | KCNA5KCNH2CYP3A4 | |
| SCHEMBL1242035 | 0.65 | KCNA5 (0.43) | KCNA5KCNH2 | |
| SCHEMBL1240326 | 0.64 | KCNA5 (0.74) | KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885CYP51A1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.